Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.67 -0.03 (-0.00%) Dow
39,056.39 +172.13 (+0.44%) Nasdaq
16,302.76 -29.80 (-0.18%) Bitcoin USD
61,675.13 -1,375.33 (-2.18%) CMC Crypto 200
1,309.59 +14.92 (+1.15%)
Cumberland Pharmaceuticals Inc. (CPIX)
After hours:
| Previous close | 1.5800 |
| Open | 1.7316 |
| Bid | 1.2900 x 200 |
| Ask | 2.1500 x 200 |
| Day's range | 1.6500 - 1.7800 |
| 52-week range | 1.4200 - 2.3600 |
| Volume | |
| Avg. volume | 10,445 |
| Market cap | 23.675M |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders' equity.
- PR Newswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
- PR Newswire
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants.
